Reference

Nonisotopic rapid method and kit for measurement of levels of therapeutic compounds

Nonisotopic rapid method and kit for measurement of levels of therapeutic compounds. Gan, Zhibo; Wallman, Jeanette; Teodorescu, Marius (USA ). U.S.In this study， 9001-92-7 and 161814-49-9 are also used. Pat. Appl. Publ. US 2003027193 A1 6 Feb 2003,10 pp. (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61K031-70. ICS: G01N033-543; C12Q001-70; C12Q001-68; A01N043-04; G01N033-53; G01N033-542; C12Q001-37. NCL: 435006000; 436518000; 514044000; 435023000; 435005000; 435007900. APPLICATION: US 2002-201143 23 Jul 2002. PRIORITY: US 2001-PV307570 23 Jul 2001. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) The invention discloses a method, kit, and assay for measuring levels of a therapeutic compd. in a sample by providing a reaction vessel contg. a sample, the sample including a therapeutic compd. having a biol. activity and biol. substance. A probe coated with a substrate for the biol. substance is provided, the substrate having a detectable label. The probe is inserted into the reaction vessel such that the therapeutic compd. and the substrate contact the biol. substance and interact within the biol. substance resulting in the label being released. The probe is removed from the reaction vessel and the quantity of detectable label is measured, thereby measuring the level of therapeutic compd. The concn. of therapeutic compd. is calcd. based upon a std. curve or by calcg. the percentage of inhibition and expressing the results in arbitrary units. .

Quantitative prediction of drug resistance in HIV-1 by correlating genotypic information with phenotypic profiles

All Rights Reserved.Some chemicals with cas registry numbers like 161814-49-9 are also used. Quantitative prediction of drug resistance in HIV-1 by correlating genotypic information with phenotypic profiles. Van Marck, Herwig Gaston Emiel; Van Den Bulcke, Tim Gerrit; Vermeiren, Hans Victor (Belg. ). U.S. Pat. Appl. Publ. US 2007020615 A1 25 Jan 2007,41pp. (English). (United States of America). CODEN: USXXCO. INCL: 435005000; 435006000; 702020000. APPLICATION: US 2005-559899 6 Dec 2005. PRIORITY: EP 2003-101687 10 Jun 2003; US 2003-478780P 16 Jun 2003; WO 2004-EP51084 10 Jun 2004. DOCUMENT TYPE: Patent CA Section: 9 (Biochemical Methods) Section cross-reference(s): 1, 10 The present invention concerns methods and systems for anal. of drug resistance in HIV-1. More specifically, the invention provides methods and algorithms for predicting drug resistance by correlating genotypic information with phenotypic profiles using a linear regression anal. The methods allow the identification of primary and secondary resistance-assocd. mutations for new and existing drugs and for calcg. the contribution of mutations and combinations of mutations to resistance and hyper-susceptibility. The invention allows the design, optimization and assessment of the efficiency of a therapeutic regimen based upon the genotype of the disease affecting a patient. .